News | November 10, 2025
AstraZeneca delivers double-digit growth
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Subscribe To Our Newsletter & Stay Updated
